Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Supernus Pharmaceuticals achieves record revenues, faces generic competition in 2022

Supernus Pharmaceuticals delivered a strong financial performance in 2022, driven by record revenues and successful product launches.
While facing challenges from generic competition, the company's focus on growth brands and pipeline assets offers opportunities for future expansion and innovation.
Strategic financial management and market adaptation will be crucial for Supernus Pharmaceuticals to navigate challenges and capitalize on growth prospects in 2023.
With a solid financial foundation and a commitment to innovation, the company is poised to pursue growth opportunities and enhance shareholder value in the pharmaceutical sector.

Supernus Pharmaceuticals reports Q1 revenue growth, faces Trokendi XR challenges

Supernus Pharmaceuticals delivered a mixed performance in Q1 2023, with strong revenue but challenges in Trokendi XR sales.
The company's financial strength, strategic guidance revisions, and pipeline progress position it for future growth.
Opportunities lie in leveraging cash reserves, driving key product sales, and advancing pipeline programs for sustained growth.
Addressing challenges in Trokendi XR sales and maintaining competitive positioning will be crucial for Supernus Pharmaceuticals' success.

Supernus Pharmaceuticals reports Q2 growth driven by Qelbree success

Supernus Pharmaceuticals showcased strong performance in Q2 2023, driven by Qelbree and GOCOVRI growth, despite Trokendi XR sales decline.
While facing challenges with Trokendi XR, the company's pipeline progress and strategic focus on key products offer growth opportunities.
Management's financial guidance reiteration for 2023 reflects confidence in the company's ability to navigate challenges and capitalize on strengths.
Overall, Supernus Pharmaceuticals remains positioned for growth through product innovation and market expansion strategies.

Supernus Pharmaceuticals reports robust Q3 performance amidst revenue challenges

Supernus Pharmaceuticals delivered a strong performance in Q3 2023 driven by Qelbree and GOCOVRI, showcasing revenue growth and promising product milestones.
While facing challenges with Trokendi XR sales decline and financial losses, the company maintains a positive outlook with revised full-year guidance and a solid cash position.
Opportunities lie in leveraging product strengths, advancing pipeline studies, and utilizing available resources to sustain growth and navigate challenges effectively.

Supernus Pharmaceuticals reports robust earnings, eyes CNS market expansion

Supernus Pharmaceuticals delivered strong financial performance in Q4 2023 and full year 2023, supported by record sales and stable earnings.
The company's transition to growth products, strong cash reserves, and strategic focus on CNS present a promising outlook for future growth.
While challenges exist in product transitions and market dynamics, Supernus is well-positioned to capitalize on opportunities in the CNS space.
By leveraging its strengths, addressing challenges, and seizing opportunities, Supernus Pharmaceuticals aims for sustained growth and market leadership.

Supernus Pharmaceuticals reports robust Q1 performance amidst pipeline opportunities

Supernus Pharmaceuticals demonstrated strong performance in Q1 2024, driven by Qelbree's growth, while facing challenges in the Parkinson's franchise.
The company's financial stability is evident with a healthy cash position and reiterated full-year revenue guidance.
Exciting opportunities exist in the CNS pipeline, but addressing setbacks like the FDA response for SPN-830 is crucial.
Strategic actions are needed to navigate the impact of generics on existing products and capitalize on upcoming catalysts.

Supernus Pharmaceuticals reports strong Q2 earnings and raises 2024 guidance

Supernus Pharmaceuticals demonstrated solid financial performance and growth in Q2 2024, driven by key products and pipeline advancements.
While facing regulatory uncertainties and operational challenges, the company's strong cash position and raised guidance signal resilience and strategic foresight.
Opportunities lie in expanding the CNS pipeline, optimizing gross-to-net deductions, and leveraging financial strength for future growth initiatives.

Supernus Pharmaceuticals reports strong Q3 performance and raises revenue guidance

Supernus Pharmaceuticals demonstrated robust financial performance and product growth in Q3 2024, driven by key products and pipeline advancements.
While facing challenges with certain product sales and pricing strategies, the company remains well-positioned for future opportunities and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that it has paid the total principal amount due of $402.5 million under its 0.625% Convertible Senior Notes due 2023 (2023 Notes), in addition to payment of the remaining outstanding interest due of $1.3 million. Following the repayment, the 2023 Notes are no longer outstanding. The repayment of the 2023 Notes at maturity was financed primarily with available cash on hand and, to a lesser extent, through a borrowing under the Company's existing credit line agreement.

Supernus Announces Repayment of Convertible Notes

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 a.m. ET.

Supernus to Present at the Cowen 43rd Annual Health Care Conference

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants David Amsellem - Piper Sandler Andrew Tsai - Jefferies Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates

1 Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.

Supernus Announces Fourth Quarter and Full Year 2022 Financial Results

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?

ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”) providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time.

Supernus Enters Into $150 Million Credit Facility

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:30 a.m. ET.

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon and welcome to Supernus Pharmaceuticals' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call Transcript

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a Company overview and update, as well as host investor meetings, at the following November conferences:

Supernus to Present at Two November Healthcare Conferences

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022.

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the SPN-830 New Drug Application (NDA). SPN-830 is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD).

Supernus Provides Regulatory Update on SPN-830

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:35 a.m. ET.

Supernus to Present at the 2022 Wells Fargo Healthcare Conference

Shares have fallen by 30% over 5 years and have risen by 15% in 2022. CNS specialist has a rich 30+ year history, varied approved product portfolio and deep pipeline.

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Clean Harbors

Eneti Inc

CLH, NETI and SUPN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2022.

Best Momentum Stocks to Buy for August 8th

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Ken Cacciatore - Cowen Operator Good afternoon and welcome to Supernus Pharmaceuticals' Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter of 2022, and associated Company developments.

Supernus Announces Second Quarter 2022 Financial Results

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2022 after the market closes on Thursday, August 4, 2022.

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

Veru

They're already raking in revenue, and more is on the way.

2 Small-Cap Stocks With Large-Cap Potential

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals' First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2022 Results - Earnings Call Transcript

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced preliminary financial results for the first quarter of 2022, and associated Company developments.

News for Supernus Pharmaceuticals Stock (SUPN)